These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11985524)

  • 1. High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy.
    Manandhar R; Shrestha N; Butlin CR; Roche PW
    Clin Exp Immunol; 2002 May; 128(2):333-8. PubMed ID: 11985524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recurrence of leprosy reactional episodes could be associated with oral chronic infections and expression of serum IL-1, TNF-alpha, IL-6, IFN-gamma and IL-10.
    Motta AC; Furini RB; Simão JC; Ferreira MA; Komesu MC; Foss NT
    Braz Dent J; 2010; 21(2):158-64. PubMed ID: 20640364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.
    Iyer A; Hatta M; Usman R; Luiten S; Oskam L; Faber W; Geluk A; Das P
    Clin Exp Immunol; 2007 Nov; 150(2):210-6. PubMed ID: 17937676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cortisol and proinflammatory cytokine profiles in type 1 (reversal) reactions of leprosy.
    Chaitanya VS; Lavania M; Nigam A; Turankar RP; Singh I; Horo I; Sengupta U; Jadhav RS
    Immunol Lett; 2013; 156(1-2):159-67. PubMed ID: 24189521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy-Associated IL-15 Production Is Involved in the Pathogenesis of Leprosy Type 1 Reaction.
    Silva BJA; Bittencourt TL; Leal-Calvo T; Mendes MA; Prata RBDS; Barbosa MGM; Andrade PR; Côrte-Real S; Sperandio da Silva GM; Moraes MO; Sarno EN; Pinheiro RO
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone.
    Roche PW; Theuvenet WJ; Le Master JW; Butlin CR
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):340-7. PubMed ID: 9934360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines in leprosy, I. Serum cytokine profile in leprosy.
    Moubasher AD; Kamel NA; Zedan H; Raheem DD
    Int J Dermatol; 1998 Oct; 37(10):733-40. PubMed ID: 9802682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia.
    Lambert SM; Alembo DT; Nigusse SD; Yamuah LK; Walker SL; Lockwood DN
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004502. PubMed ID: 27046330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ T regulatory cells and Th17 cytokines in paired samples of leprosy type 1 and type 2 reactions.
    Costa MB; Hungria EM; Freitas AA; Sousa ALOM; Jampietro J; Soares FA; Stefani MMA
    PLoS One; 2018; 13(6):e0196853. PubMed ID: 29883464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Roles of Th17 and Th1 Cells in Inflammatory Responses Associated with the Presentation of Paucibacillary Leprosy and Leprosy Reactions.
    Santos MB; de Oliveira DT; Cazzaniga RA; Varjão CS; Dos Santos PL; Santos MLB; Correia CB; Faria DR; Simon MDV; Silva JS; Dutra WO; Reed SG; Duthie MS; de Almeida RP; de Jesus AR
    Scand J Immunol; 2017 Jul; 86(1):40-49. PubMed ID: 28426172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD.
    Sasiain MC; de la Barrera S; Fink S; Finiasz M; Alemán M; Fariña MH; Pizzariello G; Valdez R
    Clin Exp Immunol; 1998 Nov; 114(2):196-203. PubMed ID: 9822276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.
    Stefani MM; Guerra JG; Sousa AL; Costa MB; Oliveira ML; Martelli CT; Scollard DM
    BMC Infect Dis; 2009 May; 9():75. PubMed ID: 19473542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.
    Andersson AK; Chaduvula M; Atkinson SE; Khanolkar-Young S; Jain S; Suneetha L; Suneetha S; Lockwood DN
    Infect Immun; 2005 Jun; 73(6):3725-33. PubMed ID: 15908402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of host-protective (IFN-gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF-alpha) cytokines by PBMC from leprosy patients stimulated with mycobacterial antigens.
    Machado P; Abrams J; Santos S; Brennan P; Barral A; Barral-Netto M
    Eur J Dermatol; 1998 Mar; 8(2):98-103. PubMed ID: 9649657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions.
    Geluk A; van Meijgaarden KE; Wilson L; Bobosha K; van der Ploeg-van Schip JJ; van den Eeden SJ; Quinten E; Dijkman K; Franken KL; Haisma EM; Haks MC; van Hees CL; Ottenhoff TH
    J Clin Immunol; 2014 Feb; 34(2):245-55. PubMed ID: 24370984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy.
    Hussain R; Kifayet A; Dojki M; Dockrell HM
    Immunology; 1999 Oct; 98(2):238-43. PubMed ID: 10540222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies.
    Forastiero RR; Martinuzzo ME; de Larrañaga GF
    Lupus; 2005; 14(2):129-36. PubMed ID: 15751817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene set signature of reversal reaction type I in leprosy patients.
    Orlova M; Cobat A; Huong NT; Ba NN; Van Thuc N; Spencer J; Nédélec Y; Barreiro L; Thai VH; Abel L; Alcaïs A; Schurr E
    PLoS Genet; 2013; 9(7):e1003624. PubMed ID: 23874223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
    Lockwood DN; Darlong J; Govindharaj P; Kurian R; Sundarrao P; John AS
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005348. PubMed ID: 28358815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral coinfection can stress peripheral lymphocyte to inflammatory activity in leprosy.
    Motta AC; Simão JC; Furini RB; Ferreira MA; Palma PV; Komesu MC; Foss NT
    Rev Soc Bras Med Trop; 2013; 46(1):73-8. PubMed ID: 23563829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.